Outcomes of antiemetic prophylaxis in children undergoing bone marrow transplantation
Outcomes of antiemetic prophylaxis in children undergoing bone marrow transplantation
复制标题
接受骨髓移植的儿童止吐预防的结果
DOI：
--
复制
发表时间：
2002
影响因子：
4.8
通讯作者：
L. Dupuis
中科院分区：
文献类型：
--
作者：
Nma Kusnierczyk;E. Saunders;L. Dupuis
对在病童医院接受骨髓移植（BMT）的儿童进行了一项关于急性和延迟抗肿瘤和辐射引起的恶心和呕吐控制的前瞻性调查。记录既往的抗肿瘤药物或放疗，开始调理方案前预期恶心或呕吐的存在，调理后24小时内使用止吐剂，规定的抗肿瘤和/或放射消融方案，以及规定的止吐方案。在调理方案的每一天以及之后的96小时内监测呕吐事件、饮食摄入、调理剂和止吐剂的使用以及不良反应。3岁以上的儿童在每个研究日评估他们的恶心程度。25名儿童随访258个病人日。患儿在急性期和延迟期分别有73%和43%的患者日没有呕吐或干呕。对21名儿童200个病人日的恶心数据进行评估。急性期和延迟期分别有55%和26%的患者日没有出现恶心。在整个研究期间，有5名儿童从未出现过呕吐。一名儿童在整个研究期间完全没有恶心和呕吐。抗肿瘤和辐射引起的恶心和呕吐在大多数接受BMT的儿童中是可以成功预防的。然而，在止吐失败的情况下，必须制定有效的治疗策略，并对不能耐受地塞米松的儿童进行有效的预防。
A prospective survey of the control of acute and delayed antineoplastic and radiation-induced nausea and vomiting was undertaken in children undergoing bone marrow transplantation (BMT) at The Hospital for Sick Children. Prior administration of antineoplastic agents or irradiation, presence of anticipatory nausea or vomiting prior to starting the conditioning regimen, antiemetic use within 24 h of conditioning, the prescribed antineoplastic and/or radiation ablative regimen, and prescribed antiemetic regimens were recorded. Emetic episodes, dietary intake, administration of conditioning agents and antiemetics, and adverse effects were monitored on each day of the conditioning regimen and for 96 h thereafter. Children older than 3 years of age assessed their nausea on each study day. Twenty-five children were followed for 258 patient days. Children did not vomit or retch on 73% and 43% of patient days, in the acute and delayed phases, respectively. Nausea data were evaluable for 21 children on 200 patient days. Nausea was absent on 55% and 26% of patient days in the acute and delayed phases, respectively. Five children never had an emetic episode during the entire study period. One child was completely free from nausea and vomiting throughout the study period. Antineoplastic and radiation-induced nausea and vomiting can be successfully prevented in the majority of children undergoing BMT. However, effective treatment strategies must be developed in the event of antiemetic failure and for effective prophylaxis in children who cannot tolerate dexamethasone.